Inactive Instrument

Intellipharmaceutics International Inc. Stock Toronto S.E.

IPCI.H

CA4581733090

Valuation: Intellipharmaceutics International Inc.

Market Cap	1.41M 1.21M 1.13M 1.03M 1.95M 134M 1.97M 13.32M 5.19M 67.65M 5.28M 5.17M 224M	P/E 2021	-0.69x	P/E 2022	-0.82x
Enterprise Value	3.65M 3.13M 2.93M 2.68M 5.05M 348M 5.1M 34.56M 13.45M 175M 13.7M 13.4M 581M	EV / Sales 2021	-	EV / Sales 2022	70.4x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Press Releases: Intellipharmaceutics International Inc.

20-08-17

Kahn Swick & Foti, LLC : Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock

More press releases

Managers and Directors: Intellipharmaceutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	2007-03-31
Christian Akyempon PRN	Corporate Officer/Principal	-	2014-01-31

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	2004-08-31

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	-.--%	-11.11%	-	-	33
ELI LILLY AND COMPANY	-1.06%	+0.65%	+77.42%	+122.82%	1,100B
JOHNSON & JOHNSON	+0.04%	+0.75%	+53.10%	+64.29%	658B
ABBVIE INC.	+0.48%	+2.65%	+28.06%	+81.19%	470B
ROCHE HOLDING AG	-1.04%	+0.73%	+42.79%	+42.81%	372B
NOVARTIS AG	-0.70%	+0.30%	+25.89%	+40.95%	304B
ASTRAZENECA PLC	-1.42%	+2.17%	+3.71%	+13.96%	264B
AMGEN INC.	-0.36%	+3.99%	+53.31%	+72.49%	239B
NOVO NORDISK A/S	-0.25%	+2.60%	-12.45%	-52.47%	213B
GILEAD SCIENCES, INC.	+1.38%	+3.72%	+30.33%	+93.56%	184B
Average	-0.08%	+3.01%	+33.57%	+53.29%	422.54B
Weighted average by Cap.	+0.00%	+2.21%	+45.68%	+71.26%

	2021	2022
Net sales	-	65.73K 56.32K 52.77K 48.21K 90.98K 6.27M 91.87K 623K 242K 3.16M 247K 241K 10.47M
Net income	-5.15M -4.41M -4.13M -3.77M -7.12M -491M -7.19M -48.73M -18.97M -247M -19.32M -18.9M -820M	-2.89M -2.48M -2.32M -2.12M -4M -276M -4.04M -27.39M -10.66M -139M -10.86M -10.62M -461M
Net Debt	1.15M 982K 920K 840K 1.59M 109M 1.6M 10.85M 4.22M 55.09M 4.3M 4.21M 182M	2.24M 1.92M 1.8M 1.64M 3.1M 214M 3.13M 21.24M 8.27M 108M 8.42M 8.24M 357M

Intellipharmaceutics International Inc. Stock Toronto S.E.

Stocks

IPCI.H

CA4581733090

Pharmaceuticals

Valuation: Intellipharmaceutics International Inc.

Press Releases: Intellipharmaceutics International Inc.

Managers and Directors: Intellipharmaceutics International Inc.

Other Pharmaceuticals

Financials

Company Profile